ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016
Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Impacts on health outcomes and on resources utilization for anticancer drugs injection at home, a complex intervention: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Article
- Home-Based Daratumumab in Patients With Multiple Myeloma.European journal of haematology · 2025Observational
- Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.Clinical and experimental medicine · 2025Article
- Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.Current hematologic malignancy reports · 2025Review
- National expert consensus on home-administered oncologic therapies in Spain.Frontiers in oncology · 2024Article
- Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.Advances in therapy · 2023Article
- Bibliometric analysis of cancer care operations management: current status, developments, and future directions.Health care management science · 2022Review
- Pediatric palliative care at home by Home Care Unit: how home nurses feel?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Observational
- [Preliminary exploration of home treatment of bortezomib in China].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.Breast (Edinburgh, Scotland) · 2020Observational
- Design of a Training Model for Remote Management of Patients Hospitalized at Home.Journal of medical and biological engineering · 2020Article
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.Blood cancer journal · 2018Review
- Safety and comfort of domestic bortezomib injection in real-life experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At home injectable chemotherapy for patients receiving treatment for hematological diseases is still in debate. Given the expense of new innovative medicines, at home treatment has been proposed as a suitable option for improving patient quality of life and decreasing treatment costs. We decided to assess the cost of bortezomib administration in France among multiple myeloma patients from an economic standpoint. Patients in this study were treated within a regional hematological network combining outpatient hospital care and Hospital care at Home administration. To make the cost comparison, our team simulated outpatient hospital care expenses. Fifty-four consecutive multiple myeloma patients who received at least one injection of bortezomib in Hospital care at Home from January 2009 to December 2011 were included in the study. The median number of injections was 12 (range 1-44) at home and 6 (range 0-30) in the outpatient care unit. When compared with the cost simulation of outpatient hospital care alone, bortezomib administration with combined care was significantly less expensive for the National Health Insurance (NHI) budget. The mean total cost per patient and per injection was 954.20 € for combined outpatient and Hospital care at Home vs 1143.42 € for outpatient hospital care alone. This resulted in an estimated 16.5 % cost saving (Wilcoxon signed-rank test, p < 0.0001). The greatest savings were observed in administration costs (37.5 % less) and transportation costs (68.1 % less). This study reflects results for a regionally implemented program for multiple myeloma patients treated with bortezomib in routine practice in a large rural area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.